The mainboard initial public offering (IPO) of Goa-based point-of-care testing major Molbio Diagnostics Limited opened for public bidding today, Monday, August 10, 2026.
Priced in a band of ₹768 to ₹807 per share, the company is looking to raise ₹939.70 crore from the primary market. By the end of its first day of bidding, central exchange data showed an overall subscription rate of 0.83 times, with institutional buyers filling up their quota right on Day 1.
The issue will remain open for bidding over a three-day window, closing on Wednesday, August 12, 2026.
Here is a plain-English, detailed breakdown of how Day 1 went, how the company makes its money, its financial track record, grey market numbers, and what you should consider before applying.
1. Day 1 Subscription Data Breakdown
By 5:00 PM on Day 1, total bids were received for 67,85,460 equity shares against the net offer size of 81,58,529 equity shares (excluding anchor allocations and employee reservations). At the upper price band of ₹807 per share, this means investors submitted application checks worth about ₹547.59 crore on Day 1.
Here is how each category performed on the opening day:
+-----------------------------------------------------------------------------------+ | MOLBIO DIAGNOSTICS LIMITED: DAY 1 SUBSCRIPTION DATA | +-------------------+-----------------+------------------+------------------+-------+ | Category | Shares Offered | Shares Bid For | Subscription (x) | Value | +-------------------+-----------------+------------------+------------------+-------+ | QIB (Institutions)| 23,25,146 | 23,33,574 | 1.00x | ₹188Cr| | NII / HNI (Wealth)| 17,43,859 | 12,77,352 | 0.73x | ₹103Cr| | RII (Retail) | 40,69,004 | 31,31,028 | 0.77x | ₹253Cr| +-------------------+-----------------+------------------+------------------+-------+ | Total Net Offer | 81,58,529 | 67,85,460 | 0.83x | ₹548Cr| +-------------------+-----------------+------------------+------------------+-------+
How to Read These Day 1 Numbers:
- Qualified Institutional Buyers (QIB - 1.00x): Institutional funds stepped in right out of the gate, fully subscribing their net quota of 23.25 lakh shares on the very first day. Institutional investors usually wait until Day 3 to place their bids, so a 1.00x QIB start on Day 1 shows genuine fund-level interest.
- Retail Individual Investors (RII - 0.77x): Everyday retail accounts placed bids for 31.31 lakh shares against 40.69 lakh shares reserved for them, filling 77% of their quota. The minimum retail application lot is 18 shares, requiring ₹14,526 at the upper price boundary.
- Non-Institutional Investors (NII / HNI - 0.73x): High-net-worth investors submitted bids for 12.77 lakh shares out of 17.44 lakh shares on offer, achieving 73% coverage (with small-HNI accounts leading at 0.80x and big-HNI accounts at 0.70x).
Strong Institutional Anchor Placement:
Before opening to the general public, Molbio Diagnostics raised ₹281.46 crore from institutional anchor investors on Friday, August 7, 2026. A total of 34,87,717 shares were allocated to anchor funds at ₹807 per share. Marquee domestic mutual funds and global institutional accounts participated in this anchor allotment, giving the company a solid institutional backing ahead of the public launch.
2. Unlisted Grey Market Premium (GMP) & Expected Listing Gains
In the unofficial grey market, shares of Molbio Diagnostics are trading at a healthy premium over the offer price:
- Issue Price Band: ₹768 to ₹807 per share
- Current Grey Market Premium (GMP): Around +₹115 to +₹130 per share
- Estimated Listing Price Range: ₹922 to ₹937 per share
- Projected Listing Gain: Approximately 14.2% to 16.1%
- Estimated Subject-to-Sauda (Retail Lot): Around ₹1,800 to ₹2,100 per application lot
What’s Supporting the Grey Market Premium?
The grey market interest is mostly driven by Molbio's unique business model. Unlike standard diagnostic chains that run brick-and-mortar blood testing labs, Molbio sells portable, high-tech molecular diagnostic testing machines and recurring test cartridges. That "razor-and-blade" model (selling the machine once and making money continuously on the test kits) gives it high gross margins.
(Note: Grey market premiums are informal indicators traded outside official exchanges. They move around based on daily market mood and shouldn't be taken as a guaranteed listing price.)
3. Business Overview: What Does Molbio Diagnostics Actually Do?
Founded in 2000 and operating out of manufacturing facilities in Goa and Visakhapatnam, Molbio Diagnostics is a point-of-care (POC) molecular diagnostics technology company.
In simple terms, traditional molecular diagnostic tests (like PCR tests for infectious diseases) usually require large, expensive laboratories, climate-controlled environments, highly trained technicians, and days of waiting time for results. Molbio changed that equation by building a portable alternative.
+-----------------------------------------------------------------------------------+ | MOLBIO DIAGNOSTICS BUSINESS SNAPSHOT | +-----------------------------------+-----------------------------------------------+ | Flagship Innovation | 'Truenat' Real-Time Micro-PCR Platform | +-----------------------------------+-----------------------------------------------+ | Device Characteristics | Portable, battery-operated, lab-quality | | | testing in under 1 hour in remote locations | +-----------------------------------+-----------------------------------------------+ | Global Endorsements | Endorsed by WHO (World Health Organization) | | | for initial Tuberculosis (TB) testing | +-----------------------------------+-----------------------------------------------+ | Disease Testing Range | 43+ diagnostic assays covering 30+ diseases | | | (TB, COVID-19, HIV, Hepatitis B/C, HPV, etc.) | +-----------------------------------+-----------------------------------------------+ | Geographic Footprint | Deployed across 90+ countries globally | +-----------------------------------+-----------------------------------------------+ | Backers / Private Equity | Temasek Holdings, Motilal Oswal Private Equity| +-----------------------------------+-----------------------------------------------+
The Core Business Drivers:
1. The 'Truenat' Platform Moat
Molbio's core growth driver is its proprietary Truenat platform. Truenat is a small, battery-operated micro-PCR system that can be carried in a briefcase to rural clinics, primary healthcare centers, or field locations. It runs tests on disease-specific cartridges and gives accurate, lab-grade PCR results in roughly one hour without requiring a permanent lab setup or stable electricity.
2. World Health Organization (WHO) Endorsement
Getting approved by global health bodies is a massive hurdle in medical diagnostic tech. Truenat is officially endorsed by the World Health Organization (WHO) as an initial diagnostic test for tuberculosis (TB) and multi-drug resistant TB (MDR-TB). This official endorsement allows Molbio to bid for large government healthcare tenders and international public health programs supported by global aid organizations.
3. Recurring Revenue Model
When Molbio sells a Truenat testing device to a hospital, diagnostic chain, or government health program, it creates an ongoing revenue channel. Every device needs a constant supply of consumable, single-use test cartridges. Over time, recurring cartridge sales generate far more revenue and higher margins than the initial hardware sale.
4. Detailed Financial Performance (FY24 to FY26)
An analysis of Molbio Diagnostics' restated consolidated financial statements shows fast top-line scaling along with strong operational profitability over the last three fiscal years.
+-----------------------------------------------------------------------------------+ | MOLBIO DIAGNOSTICS: 3-YEAR FINANCIAL PERFORMANCE | +-------------------------------+-------------------+-------------------+-----------+ | Financial Metric (₹ in Cr) | FY24 | FY25 | FY26 | +-------------------------------+-------------------+-------------------+-----------+ | Revenue from Operations | 840.66 | 1,027.94 | 1,455.17 | | Total Assets | 1,221.06 | 1,461.56 | 2,148.42 | | EBITDA | 185.09 | 256.64 | 328.24 | | EBITDA Margin (%) | 22.02% | 24.97% | 22.56% | | Net Profit After Tax (PAT) | 83.54 | 138.58 | 164.14 | | PAT Margin (%) | 9.94% | 13.48% | 11.28% | | Total Borrowings / Debt | 174.58 | 123.16 | 412.64 | | Net Worth | 807.94 | 952.95 | 1,144.68 | | Return on Equity (ROE %) | 10.34% | 16.20% | 15.59% | +-------------------------------+-------------------+-------------------+-----------+
Key Financial Observations:
- Revenue Growth: Revenue from operations grew from ₹840.66 crore in FY24 to ₹1,455.17 crore in FY26. That is a 2-year growth rate of 73.1%, driven by expanding sales of Truenat devices and growing cartridge demand across India and international markets.
- Profit Margins: Net profit rose from ₹83.54 crore in FY24 to ₹164.14 crore in FY26. EBITDA margins have stayed healthy in the 22% to 25% range, showing that the business maintains strong operational pricing power even as it scales up production.
- Debt Increase: Borrowings increased to ₹412.64 crore in FY26 (up from ₹123.16 crore in FY25) as the company expanded manufacturing capacity and invested in R&D infrastructure. However, relative to its net worth of ₹1,144.68 crore, its debt-to-equity ratio remains manageable at ~0.36x.
5. Offer Structure & Objects of the Issue
The ₹939.70 crore public issue is structured as follows:
+-----------------------------------------------------------------------------------+ | IPO CAPITAL STRUCTURE BREAKDOWN | +-----------------------------------+-----------------------------------------------+ | Total Issue Size | ₹939.70 Crore (1,16,46,246 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Fresh Issue Component | ₹200.00 Crore (24,80,246 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Offer for Sale (OFS) Component | ₹739.70 Crore (91,66,000 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Price Band | ₹768 to ₹807 per share | +-----------------------------------+-----------------------------------------------+ | Face Value | ₹1 per share | +-----------------------------------+-----------------------------------------------+ | Employee Reservation | 20,520 Shares (Discount of ₹76/share) | +-----------------------------------+-----------------------------------------------+ | Lead Managers (BRLMs) | Kotak Capital, IIFL Capital, Jefferies India, | | | Motilal Oswal Investment Advisors | +-----------------------------------+-----------------------------------------------+ | Registrar to the Issue | KFin Technologies Limited | +-----------------------------------+-----------------------------------------------+
How Will the Fresh Money Be Used?
Out of the ₹939.70 crore total issue, ₹200 crore is fresh capital that goes straight to the company balance sheet. Molbio plans to spend these proceeds as follows:
- R&D Facility & Center of Excellence Construction (₹125.12 Crore): Building a new research and development center, Center of Excellence, and corporate headquarters in Goa to design next-generation diagnostic devices.
- Machinery & Equipment Purchase (₹80.81 Crore): Buying automated assembly lines and specialized equipment for Goa Unit I, Goa Unit II, and Visakhapatnam manufacturing plants to boost test cartridge production capacity.
- General Corporate Purposes: The balance will support administrative expenses and global sales expansion.
Understanding the Offer for Sale (OFS):
The larger part of the issue—₹739.70 crore (78.7% of the total issue)—is an Offer for Sale by existing shareholders, including private equity investors like Temasek and Motilal Oswal PE. This money goes directly to the selling shareholders. Promoter shareholding will drop slightly from 46.65% pre-issue to around 43.01% post-issue.
6. Valuation Analysis & Peer Comparison
At the top price band of ₹807 per share, Molbio Diagnostics is priced at a trailing Price-to-Earnings (P/E) multiple of 56.67x based on its post-issue diluted FY26 EPS of ₹14.24 (or ~55.4x based on pre-issue EPS of ₹14.56).
Let's compare this with listed health-tech and diagnostic companies in the Indian stock market:
+-----------------------------------------------------------------------------------+ | PEER GROUP VALUATION COMPARISON | +-----------------------------------+--------------------+--------------------------+ | Company Name | Trailing P/E (x) | Primary Focus / Model | +-----------------------------------+--------------------+--------------------------+ | Molbio Diagnostics Ltd (At ₹807) | ~56.67x | POC Diagnostic Devices | | Dr. Lal PathLabs Ltd | ~62.10x | Pathology Lab Network | | Metropolis Healthcare Ltd | ~54.30x | Diagnostic Testing Chain | | Poly Medicure Ltd | ~68.50x | Medical Consumables/Tech | +-----------------------------------+--------------------+--------------------------+
Valuation Summary:
A P/E of 56.67x is certainly not cheap, but medical technology and diagnostic device makers with proprietary, patent-backed products generally demand a scarcity premium over standard diagnostic lab chains. Given its 41.6% revenue growth in FY26 and 22.5%+ EBITDA margins, the market is pricing Molbio as a medical technology platform rather than a simple testing lab.
7. Core Strengths vs. Key Business Risks
Here is a quick summary of the main arguments for and against the company:
Key Business Strengths:
- Patented & WHO-Approved Tech: Truenat's WHO endorsement for TB testing gives it a massive competitive edge when bidding for international government healthcare projects.
- Recurring Revenue Stream: High-margin cartridge sales provide recurring, predictable income once testing hardware is installed at client sites.
- Strong Institutional Backing: Private equity backing from Temasek and Motilal Oswal PE, plus a fully covered QIB book on Day 1, shows strong institutional confidence.
- Global Footprint: Operating in 90+ countries reduces reliance on any single regional market.
Key Business Risks:
- High Reliance on TB Testing: Tuberculosis test kits generate over 70% of total revenue. Any change in government health budgets or competing diagnostic breakthroughs for TB could impact sales.
- Dependence on Government Tenders: A big chunk of sales comes from state/central health department orders and international public health agencies. Delayed tender cycles or policy changes can cause uneven quarterly revenue.
- Large OFS Portion: Almost 79% of the total IPO money goes to selling private equity investors rather than building new company assets.
- Rich Valuation: At ~56.7x P/E, the stock leaves little room for operational missteps or quarterly earnings misses post-listing.
8. Application Matrix & Timeline
If you're planning to apply for the Molbio Diagnostics IPO, here are the key application details and upcoming dates:
- Bidding Closes: Wednesday, August 12, 2026 (5:00 PM IST)
- Allotment Finalization: Thursday, August 13, 2026
- Refunds & Demat Credit: Friday, August 14, 2026
- Listing Date (BSE & NSE): Monday, August 17, 2026
Investment Application Sizes:
- Retail Minimum: 1 Lot (18 Shares) — ₹14,526
- Retail Maximum: 13 Lots (234 Shares) — ₹1,88,838
- Small HNI (sNII) Minimum: 14 Lots (252 Shares) — ₹2,03,364
- Big HNI (bNII) Minimum: 69 Lots (1,242 Shares) — ₹10,02,294
Final Verdict: What Should You Watch for on Day 2 & Day 3?
Molbio Diagnostics offers a rare chance to invest in a proprietary Indian medical technology manufacturer with global reach, WHO validation, and strong top-line growth.
Day 1 saw a steady start at 0.83x overall subscription, with institutional buyers fully locking in their reserved portion right away. Over the next two days, watch if retail and HNI categories pick up speed to match the grey market's positive signals (+₹115–₹130 per share).